Division of Health Policy and Insurance Research  
The Harvard Medical School  
Fellowship in Health Policy and Insurance Research  
(Formerly Fellowship in Pharmaceutical Policy Research)

Fellows

**Alessandra Ferrario, PhD**  

Dr. Alessandra Ferrario received her doctorate from the Department of Social Policy, London School of Economics and Political Science in 2017 and was awarded a fellowship from the prestigious Swiss National Science Foundation.

During her fellowship, she will study the intensity of end-of-life care over time and its determinants among women with breast cancer who are insured by a large commercial health insurer in the US.

**Christine Leopold, PhD**

**Dr. Leopold** is a Post-Doctoral Senior Research Fellow in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She received an Erwin Schroedinger stipend from the Austrian Science Fund as well as a Thomas O. Pyle Research Scholarship from Harvard Medical School. Currently she works on various studies in which she assess the impact of policy changes (regulatory or coverage) on the utilization of metastatic breast cancer treatments by looking at trends in claims data. In addition, Dr. Leopold performed a qualitative study on the adaptability of pharmacy benefits systems to the current challenges of high-cost specialty medicines in various high-income countries. Her main research interests include ethical considerations in pharmaceutical pricing and reimbursement, evidence-based decision-making in pharmaceutical policy as well as the evaluation of the pharmaceutical policies’ impact on affordability and availability of medicines. Prior to joining the Department of Population Medicine at Harvard Medical School she co-led the Austrian Centre for Rare Disease as well as the European Network of public authorities of Pharmaceutical Pricing and Reimbursement Information (PPRI) at the Department of Health Economics at the Austrian Health Institute / WHO Collaborating Center for Pharmaceutical Pricing and Reimbursement Policies. She holds a doctorate in Pharmaceutical Policy from Utrecht University, Utrecht Institute for Pharmaceutical Science / WHO Collaborating Centre for Pharmaceutical Policy and Regulation in the Netherlands and a Master of Science degree from Bocconi University in Italy.

**Selected Publications:**


PAST FELLOWS

Isabel CM Emmerick, MS, PhD 2012-2016

Dr. Emmerick was a post-doctoral fellow in the Pharmaceutical Policy Research Fellowship at the Department of Population Medicine. Her research is in the area of improving health systems in developing countries, including research of the factors related to use of medicines and impacts of pharmaceutical policies on utilization. Her primary area of interest is to evaluate the impact of the four Brazilian subsidy policies regarding access to medicines.

As a researcher at the Center for Pharmaceutical Policies (NAF) of ENSP/FIOCRUZ in Brazil, a PAHO/WHO Collaborating Center, she participated in the formulation and support of evaluation of pharmaceutical policies, not only in Brazil but also in other countries of the Region of the Americas and Africa, and worked in permanent exchange with the medicine programs of PAHO and WHO.

Dr. Emmerick received her Bachelor of Science in Pharmacy degree from the Universidade Federal do Rio de Janeiro, Brazil and her Masters of Science and Doctorate of Science degrees in Public Health from the National School of Public Health, Oswaldo Cruz Foundation, Brazil. She also was a research scholar in the Department of Population Medicine Drug Policy Research Group in from 2009 until 2010.

Publications


Miranda, Elaine Silva; Pinto, Claudia Du Bocage Santos; REIS, Andre Luis de Almeida dos; Emmerick, Isabel Cristina Martins; Campos, Monica Rodrigues; Luiza, Vera Lucia; Osorio-De-Castro, Claudia Garcia Serpa. Lessons learnt from conducting a medicine price survey in multiple regions of Brazil. WHO Essential Medicines Monitor, issue 4, p. 1-4, April 2010.


Rebecca Haffajee, JD, MPH, PhD 2012-2016

Dr. Haffajee is an Assistant Professor of Health Management and Policy at the University of Michigan School of Public Health.

After completing her JD and MPH at Harvard in 2006, Rebecca practiced as a health care associate in the law firm of Ropes & Gray LLP for three years, where she advised domestic health care providers on regulatory compliance and reimbursement matters. From 2009-2010, she served as a Law Fellow at the O’Neill Institute for National and Global Health Law at Georgetown University Law Center. Rebecca entered the Harvard PhD Program in Health Policy in 2010 with a concentration in Evaluative Science and Statistics and received her doctorate in May 2016.

Applying sophisticated analytical methods from econometrics, epidemiology, and public health law research, Rebecca’s work combines detailed legal analysis with empirical investigations of the relationships between law and health. Her doctoral work focused on evaluating the effects of behavioral health legal interventions. She recently completed a longitudinal assessment of the effects of the federal Mental Health Parity and Equity Act (MHPAEA) on mental health treatment and outcomes.

During her fellowship in the Department of Population Medicine, Rebecca worked on an empirical analysis of the intended and unintended impacts of state prescription drug monitoring program mandates that require physicians to participate in querying the programs before prescribing controlled substances. Her work has been funded by the Robert Wood Johnson Foundation, the National Institute of Mental Health, the Department of Population Medicine, and Harvard University.

Publications:


Haffajee RL. The potential use of joint criminal enterprise theory in prosecuting crimes of rape and sexual violence at the ICTR. Harvard J Law & Gender 2006;29(1):201-221.

Ming Hu, PhD 2013-2014

Dr. Hu is an associate professor in the Department of Clinical Pharmacy and Pharmacy Administration at West China School of Pharmacy, Sichuan University. She is also the recipient of the prestigious China Medical Board Faculty Development Award. Ming conducted a range of research projects in the effectiveness evaluation of pharmaceutical policies, and economic evaluation of clinical pharmacy practice in the past 10 years. During her 6-month Pharmaceutical Policy Research Fellowship in the Drug Policy Research Group, Ming focused on the performance evaluation of the National Essential Medicine System in China.

Rosarin Sruamsiri, BPharm, MBA, PhD 2013-2014

Dr. Sruamsiri is a Health Economist at Janssen Pharmaceutical KK, Japan. Her research interests included evidence-based decision making in health care, economic evaluation, pharmacoeconomic and outcomes research. Rosarin is also interested in the evaluation of health policy with a particular focus on observational data. During her Pharmaceutical Policy Research Fellowship year in the Drug Policy Research Group, Rosarin’s research focused on the evaluation of one of the Thailand national policies, “High-cost medicine: E2 access program” which aims to increase access to expensive medicine for patients in need. She evaluated the effects of this policy on medicine utilization and health care costs in Thailand. She also reviewed the interplay of innovative policies and programs involving multiple stakeholders to facilitate access to these high-cost medicines in Thailand.


Chih-Sheng (Jason) Hsu, MSc, PhD 2011-2012, 2013-2014
Jason C. Hsu Ph.D. is an Assistant Professor at School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences in National Cheng Kung University (NCKU) in Taiwan. Jason’s academic interests include pharmaceutical regulatory science and medical decision science. He is particularly interested in the application of evidence generated from pharmacoepidemiology and pharmacoeconomics research information to decision-making in health policy and clinical practice. Jason was a Fulbright Research Fellow (2011-2012) and Postdoctoral Research Fellow (2013-2014) focusing on Pharmaceutical Policy Research at Department of Population Medicine in Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, USA. He received his Doctor of Philosophy (PhD) in International Business from National Taiwan University (NTU); his Master of Science degree in Technology Management from National Tsing Hua University (NTHU); and his Bachelor degree in Pharmacy from Taipei Medical University (TMU).

Publications:


Laura Faden Garabedian, PhD

Dr. Garabedian is an assistant professor in the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute. She is a member of the Division of Health Policy and Insurance Research (formerly the Drug Policy Research Group).

Dr. Garabedian’s research focuses on the robust evaluation of global and domestic health insurance reforms, insurer-led health system delivery reforms and pharmaceutical policies. She is also interested in the evaluation and development of analytic methods for health policy research, with a particular focus on observational data methods for comparative effectiveness research.

Dr. Garabedian received her PhD in Health Policy from Harvard University, with a specialization in evaluative science and statistics. She was a pre-doctoral Pharmaceutical Policy Research Fellow and a post-doctoral Pyle Fellow at DPM. Prior to Harvard, Dr. Garabedian worked as a research analyst at the Tufts Center for the Study of Drug Development. She has an MPH from Tufts and a BA from Boston University.
Publications:


---

**Huseyin Naci, PhD**

Dr. Huseyin Naci is an Assistant Professor of Health Policy at The London School of Economics and Political Science (LSE). Huseyin’s academic interests include research design, comparative effectiveness research, drug regulation, and health policy evaluation. His methodological research focuses on the strengths and weaknesses of study designs in determining the benefits and harms of health care interventions and policies. He is particularly interested in the application of evidence generated from randomized trials, observational studies, and network meta-analyses to decision-making in health policy and clinical practice.

Huseyin’s policy-relevant research focuses on the unintended consequences of health policies; market entry requirements for new health technologies; economic access to medications; and the role of health care professionals in caring for individuals with multiple chronic conditions.

Prior to starting his research at LSE Health, Huseyin conducted research in the areas of international health, mental health, and international development at the World Health Organization and Johns Hopkins University. Most recently, he was a Thomas O. Pyle Fellow in Population Medicine at Harvard University (2013-2014) and a Fellow in Pharmaceutical Policy Research at Harvard Medical School and Harvard Pilgrim Health Care Institute (2012-2013), both in Boston, USA.

Huseyin received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the London School of Economics and & Political Science (London, UK); his Master of Science in Public Health (MSPH) degree in International Health, with a focus on Health Economics from the Johns Hopkins University Bloomberg School of Public Health (Baltimore, MD, USA); and his Bachelor of Arts degree in Biochemistry from Knox College (Galesburg, IL, USA).

**Publications:**


Difei Wang, PhD 2012-2013

Difei Wang was a postdoctoral fellow in the Pharmaceutical Policy Research Fellowship at Harvard Medical School and Pilgrim Healthcare Institute. He received his PhD in health policy in 2012 at Tongji Medical College, Huazhong University of Science and Technology in China.

Difei is specializing in evaluating the impact of pharmaceutical policy changes on the use of medicines in China. His research interests are in studying access to and use of medicines, the price and affordability of medicines, and the selection and coverage of medicines in the Chinese national health insurance system.

Difei’s primary research topics during his fellowship year were evaluating the effects of China’s essential medicines policy on outpatients medicine use and studying the impact of social health insurance policy changes on inpatient health service and drug utilization.

Yu Fang, PhD 2012-2013

Dr. Yu Fang joined the fellowship as a recipient of the prestigious China Medical Board Faculty Development Award. He is an associate professor in the Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Health Science Center, Xian Jiaotong University. He is also the vice-dean of the School of International Education and the director of the Center for Drug Safety and Drug Policy at the University. Dr. Fang is a member of International Pharmaceutical Federation (FIP) and International Health Economics Association (iHEA). He graduated from Xian Medical University and earned his MSc in Pharmacy Administration in 2004 from Xian Jiaotong University and PhD in Pharmacy Administration from Shenyang Pharmaceutical University in 2007. In 2007 Dr. Fang was a visiting scholar in the Department of Pharmaceutical Care & Health System, School of Pharmacy in the University of Minnesota. Dr. Fang’s major research interests cover the areas of pharmaceutical policy and rational drug use in community setting. He published over 40 papers and was the editor or co-editor of 8 books.
Publications:


**Yu Fang**. China should curb non-prescription use of antibiotics in the community. *BMJ*, 2014; 348: g4233.

---

**Matthew Frank** 2011-2012

Matthew Frank was a PhD candidate in Health Policy at Harvard University. He was a recipient of a National Science Foundation Graduate Research Fellowship. Matt graduated from Northwestern University with a double major in economics and history. He then worked for over a decade in finance and consulting, and also spent several years in the nonprofit sector. In June 2009, Matthew received a master of divinity degree from Harvard Divinity School, where his research focused on bioethics and public policy. Matt’s fellowship research used both empirical and normative methods to assess how health insurance designs can improve quality and constrain spending while protecting access to care for vulnerable groups.

---

**Atle Fretheim, MD, PhD** 2011-2012

Dr. Fretheim is a Research Director at the *Norwegian Institute of Public Health*. Atle is also an Adjunct Professor at the *Institute of Health and Society, Faculty of Medicine, University of Oslo*. Dr. Fretheim’s research during his fellowship was on comparisons of results from cluster-randomized trials with those from analyses of interrupted time series data.

Publications:


---

**Bao Liu, PhD** 2011-2012

Dr. Liu joined the fellowship as a recipient of the prestigious China Medical Board Faculty Development Award. His fellowship research was on analyzing health systems data to form health care and medicines policy in China.

Dr. Liu is now a professor of health economics at the Fudan University School of Public Health, and at the Fudan University Center for Pharmacoeconomic Research and Evaluation. He is a member of Fudan University Commission of Planning and Development. Dr. Liu graduated from Shanghai Medical University in 1995 and earned his
MSc in Biostatistics in 2000 and PhD in Health Economics from Fudan University in 2003. He served for the World Health Organization in 2001 and 2005-2006 as technical officer at the Department of Health Financing and Stewardship and the Department of Chronic Diseases, respectively, dedicated to the pursuit of global health systems performance assessment and the progress evaluation of global chronic disease prevention and control. He was visiting scholar at the Johns Hopkins School of Public Health Department of Health Policy and Management in 2010. He is currently an expert member at the Chinese Price Association Specialty Committee of Medicine Price, Chinese Health Economics Association Advisory Committee of Health Policy and Technology Economic Assessment, China Pharmaceutical Innovation and Research Development Association Specialty Committee of Medicine Policy, China Medicine Education Association Standing Specialty Committee of Clinical Rational Drug Use, Shanghai Health Technology Assessment Research Center Expert Advisory Committee, and the Advisory Committee at the Institute of Medicine Economics, Sun Yat-sen University School of Pharmacy. Prof. Liu has been the Principal Investigator of many research projects funded by the World Health Organization, National Natural Science Foundation of China, Office of Deepening Healthcare System Reform of the State Council, National Health and Family Planning Commission, Ministry of Education, and Chinese Price Association. He has published 6 books and over 80 academic journal papers.

Meredith Chace, PhD

Dr. Chace received her PhD in Health Policy from Harvard University, with a concentration in evaluation sciences and statistics. Meredith received a Master of Science degree in Health Policy and Management from the Harvard School of Public Health in 2006. Meredith’s fellowship research focused on Medicare/Medicaid dual eligibles drug coverage as well as utilization and cost of care of patients with Multiple Sclerosis. She has worked as an analyst at three different companies focusing on claims data analysis for health outcomes research, health economics and pharmacoepidemiology. Her current research interests include health care access, nursing home care, and pharmaceutical policy.

Publication:


Aakanksha H. Pande, PhD

Dr. Pande is a Senior Health Economist at the World Bank Group with more than fifteen years experience working in low, middle and high income countries. She has expertise in topics related to the health impact of conflicts (Syria, Yemen etc), health sector reform, universal health coverage, and non communicable diseases, quality of care. She brings rigorous methodological expertise in impact evaluation, econometric analyses, health system diagnoses, and development of strategy.

During her fellowship, her research involved with using quasi evaluative methods to inform health policy and towards this end she has designed impact evaluations of AIDS program in South Africa and Uganda. She is a co-author of "Handbook for evaluating real
world HIV programs” (World Bank, forthcoming) and has authored papers in the academic
and non academic press (including an op-ed on her other passion -- the game of cricket--
for the New York Times!). She holds a masters and doctorate from Harvard University, an
undergraduate degree from Yale University, and was a Fox International Fellow at
Cambridge University in UK.

Publications:

Pérez-Cuevas R, Doubova SV, Suarez-Ortega M, Law M, Pande AH, Escobedo J,
Espinosa-Larrañaga F, Ross-Degnan D, Wagner AK. Evaluating quality of care for
patients with type 2 diabetes using electronic health record information in Mexico. BMC

Pande AH, Ross-Degnan D, Zaslavsky AM, Salomon JA. Effects of healthcare reforms on
coverage, access, and disparities: quasi-experimental analysis of evidence from

Bin Jiang, PhD

Dr. Bin Jiang is an associate professor of Pharmacy Administration in the Department of
Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking
University Health Science Center. Dr. Jiang has a wide range of teaching and research
experiences in pharmaceutical regulation and policy in China. Dr. Jiang was the recipient
of the prestigious China Medical Board Faculty Development Award. Bin Jiang’s
fellowship research focused on Chinese health care reform.

Li Yang, PhD

Dr. Li Yang is an associate professor at Department of Health Policy and Management,
School of Public Health, Peking University. She also serves as the Beijing chapter
representative for the ISPOR Asia Executive Committee and the editor of Chinese Journal
of Pharmaceutical economics. Her scientific expertise is pharmaceutical policy and
pharmacoeconomics, economic impact of chronic diseases and aging issue. She has
directed numerous projects on drug pricing, quality of life evaluations and cost-
effectiveness analyses, and written and lectured in pharmacoeconomics. She was involved
in monitoring and assessing the Chinese Essential Medicine Policy in 13 provinces funded
by MOH and AuID. She holds a Ph.D in health economics from Fudan University and has
been a post-doctoral researcher in the University of Vienna. Dr. Yang was also the
recipient of the prestigious China Medical Board Faculty Development Award she was a
fellow in Department of Population Medicine, Harvard Medical School and Harvard
Pilgrim Health Care Institute.

Dr. Li Yang joined the Fellowship from Peking University where she is an associate
professor in the Department of Health Policy and Management. Dr. Yang was also the
recipient of the prestigious China Medical Board Faculty Development Award. Li Yang’s
fellowship research centered on medicines policy in China.

Sheila Reiss Reddy, MSc, RPh, PhD

Sheila Reddy is Director of Health Services Research at Partnership for Health Analytic
Research. Dr. Reddy is a health services researcher and pharmacist with over 10 years of
experience in health policy research, project management, and patient care delivery. Sheila’s research has focused on health care affordability, exploring the impact of high cost sharing on access to care and on household economic stability. Core competencies include impact evaluation, health economics, outcomes research, real world data analysis, study design and outcomes measurement, global health, program evaluation management, managed care, and pharmaceutical policy.

Prior to her career in research and evaluation, Sheila practiced pharmacy in the US and worked in public health in Sub-Saharan Africa, focusing the latter on improving maternal and child health, vaccination coverage, HIV prevention, and water and sanitation for rural communities. These earlier experiences helped to inform her understanding of diverse health systems and spurred her interest in generating and using evidence to advance health policies, programs, and treatments.

Dr. Reiss received her PhD in health policy at Harvard University. Her research interests broadly include global pharmaceutical policy and disparities in access to care. She has examined how best to measure health care affordability by assessing the validity of widely used measures of economic burden due to health care payments; and she also studied whether insurance plans with the highest levels of cost-sharing reduce access to essential medicines. Her fellowship research focused on U.S. and global health policy research on health care affordability, insurance design and coverage, access to essential care and medicines, and household financial burden due to out-of-pocket health spending.

**Publications:**


**Brian Serumaga, MPH, PhD**

Dr. Serumaga is a technical advisor at John Snow Inc, and associate lecturer in primary care at University of Nottingham Medical School, UK. He holds a doctorate in primary health care and an MPH from the University of Nottingham and a Pharmacy degree. In 2009-2010, His fellowship research focused on improving the quality of health care in both developed and developing countries. He also works on identifying and analyzing the effects of policy, regulatory frameworks, and health system environments on quality of care and access to medicines. He is a member of the pharmaceutical society of Uganda, the Cochrane systematic review group on patient safety, the WHO access to medicines research network, the international society on pharmacoepidemiology and drug safety and the drug utilization research group.

**Publications:**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Journal</th>
<th>Volume</th>
<th>Pages</th>
<th>PMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009-2010</td>
<td>[Details obscured]</td>
<td>[Details obscured]</td>
<td>[Details obscured]</td>
<td>[Details obscured]</td>
<td>[Details obscured]</td>
</tr>
</tbody>
</table>

Katy Backes Kozhimannil, MPA, PhD

Dr. Kozhimannil received her PhD in Health Policy from Harvard University in 2009 and completed a postdoctoral fellowship with HP in 2010. Dr. Kozhimannil is currently an Associate Professor in the Division of Health Policy and Management at the University of Minnesota, and Director of Research at the University of Minnesota Rural Health Research Center.

Dr. Kozhimannil conducts research to inform the development, implementation, and evaluation of health policy that impacts health care delivery, quality, and outcomes during critical times in the lifecourse, including pregnancy and childbirth. The goal of her scholarly work is to contribute to the evidence base for clinical and policy strategies to advance racial, gender, and geographic equity and to collaborate with stakeholders in making policy change to address social determinants and structural injustice in order to facilitate improved health and well-being.

Dr. Kozhimannil’s research, published in major journals such as Science, the New England Journal of Medicine, JAMA, Health Affairs, American Journal of Public Health, Medical Care, and the American Journal of Managed Care, has been widely cited. Media coverage of her research, including feature stories by the New York Times, Washington Post, National Public Radio, Wall Street Journal, US News & World Report, and the Huffington Post, has generated dialogue, interest and policy action at local, state, and national levels. In addition to conducting research, Dr. Kozhimannil teaches courses that build skills for effective engagement in the policy process, and works extensively with community organizations and state and federal policy makers on efforts to improve population health, starting at birth.

Jason

Publications:


Kozhimannil KB, Adams AS, Soumerai SB, Busch AB, Huskamp HA. New Jersey's efforts to improve postpartum depression care did not change treatment patterns for women on Medicaid. Health Aff (Millwood) 2011 Feb;30(2):293-301.


Ashley J. Beard, MPH, PhD 2008-2010

Dr. Beard was a Thomas O. Pyle Research Fellow at the Department of Population Medicine. She holds an MPH in Health Behavior and Health Education at the University of North Carolina at Chapel Hill and her PhD in Pharmaceutical Outcomes and Policy at the UNC School of Pharmacy. Dr. Beard’s research interests focus on the quality and context of care for adults with multiple chronic illnesses. She is particularly interested in the intersection of informal and formal systems of care and ways to maximize the utility of both to improve medication use and patient health outcomes. Her fellowship research included examination of medical visit communication about medications, the influence of family and friend caregivers, and development of innovative interventions to facilitate medication use and caregiver support of adults with multiple chronic illnesses. In 2010, Dr. Beard became a faculty member in the University Michigan Health Services Research and Development Program.

Publications:


Christine Yi-Ju Lu, BPharm, MSc, PhD 2007-2008

Dr. Lu is an Assistant Professor in the Department of Population Medicine. She is a pharmacist, pharmacoepidemiologist, and health policy researcher. Dr. Lu received a MSc (Biopharmaceuticals) and a PhD in Clinical Pharmacology from the University of New South Wales, Australia. Her current research focuses on access to biologic medicines, genomic-based technologies, orphan drugs, and psychotropic medications. Since 2012, she also serves as Adjunct Senior Lecturer in the Faculty of Pharmacy, University of Sydney, Australia.

During her Fellowship, Dr. Lu examined the effects of prior authorization policies for atypical antipsychotic, anticonvulsant and cardiovascular medications on use of medications and health services among Medicaid beneficiaries.

Publications:


Catherine E. Vialle-Valentin, MD, MHCM

Dr. Catherine Vialle-Valentin, was Senior Research Associate in the Department of Population Medicine from 2008-2016. She received her medical degree in France where she is board certified in endocrinology. She holds a masters degree in health policy and management from the Harvard School of Public Health. Dr. Vialle-Valentin’s research is in the area of international pharmaceutical policy evaluation. During her Fellowship, she completed a study to evaluate the role of community-based health insurance schemes on access to medicines in poor settings. At present, her work is centered on methods for measuring access to and rational use of medicines in developing countries. Her main focus continues to be the development and testing of a household survey to collect in-depth information on medicines used during acute and chronic conditions, and barriers to medicines access.

Publication:


Michael R. Law, MSc, PhD

Dr. Michael Law holds the Canada Research Chair in Access to Medicines, and is an Associate Professor in the Centre for Health Services and Policy Research, School of Population and Public Health, at the University of British Columbia. Michael’s research program focuses on pharmaceutical policy. His work focuses on access to and the use of prescription drugs, including the affordability of prescription drugs, private drug insurance, generic drug pricing, and the impact of pharmacist prescribing. His research program has attracted more than $2.5 million in research funding, including 4 operating grants from CIHR as principal investigator.

He has been published in leading medical journals, including BMJ, Archives of Internal Medicine, and CMAJ. This work has been featured in news media such as New Scientist, Forbes, the Globe & Mail, and USA Today. He has also authored commentaries that have
appeared in the Toronto Star and Vancouver Sun. His research has had a major impact on
generic drug pricing in Canada, leading to policy changes that have saved governments the
country more than $100 million every year.

Since his appointment at UBC he has received several notable awards, including a
Distinguished Achievement Award from the UBC Faculty of Medicine (2012), the Labelle
Lectureship at McMaster University, the 2011 Paper of the Year Award from the Canadian
Institute for Health Services and Policy Research, a Canadian Institutes of Health Research
New Investigator Award, and a Michael Smith Foundation for Health Research Scholar
Award.

In 2015, he taught one of UBC’s first edX.org Professional Education courses on
Interrupted Time Series Analysis.

Prior to joining UBC, he completed a PhD in Health Policy at Harvard University and a
post-doctoral fellowship at Harvard Medical School, where he trained in research methods
and statistics. He has also completed an MSc from the London School of Economics, and
worked as a research associate at the University of Auckland, New Zealand.

Publications:

Soumerai SB, Law MR. Cost-effectiveness of schizophrenia pharmacotherapy. Am J
Psychiatry 2007;164:678.

Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-
generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr

Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication

Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, Lecates RF, Law MR, Hughes TE,
Chapman D, Adams AS. Use of atypical antipsychotic drugs for schizophrenia in Maine
Medicaid following a policy change. Health Aff (Millwood) 2008;27:w185-95. Epub 2008
Apr 1.

Law MR, Majumdar SR, Soumerai SB. Effect of illicit direct-to-consumer advertising on
use of etanercept, mometasone and tegaserod in Canada: a controlled longitudinal study.

Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-
consumer advertising for clopidogrel in Medicaid. Arch Intern Med. 2009;169(21):1969-
74.


Ms. Pierre-Jacques’ research interests included examining the relationship between health
policies and access to both health care services and medicines for under-served populations
including immigrants, elderly, Native Americans and low-income families. With funding
from the NIH Minority Research Training Supplement Program, she pursued research in
diabetes health disparities and medication non-adherence in the elderly and disabled. She
also completed a project in collaboration with the World Health Organization Essential Drugs and Medicines/Drug Action Programs assessing core indicators of pharmaceutical systems in 168 countries. Ms. Pierre-Jacques is in the process of pursuing a medical degree.

Publications:


Yuting Zhang, MS, PhD 2005-2007

Dr. Zhang is an Associate Professor of Health Economics and Director of the Pharmaceutical Economics Research Group in the Department of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health. During her Fellowship, Dr. Zhang’s research focused on examining whether using newer prescription drugs can save money by reducing use of other medical services (the drug-offset effect). She also co-led a successful grant application to examine economic and clinical effects of prior authorization policies among Medicaid beneficiaries with bipolar disorder. Dr. Zhang received her PhD in health policy from Harvard University.

Publications:


---

**SeongOk Kim, PhD**

Dr. Kim is a senior researcher in the National Health Insurance Corporation of Korea where she is responsible for pharmaceutical reimbursement policies and decisions about cost-effective drug use. Her Fellowship research was funded by the Fulbright Program focused on the effects of pharmacy cost containment policies on physicians’ prescribing patterns in the Korean National Health Insurance. She also interacted with colleagues at Harvard Pilgrim Health Care and Neighborhood Health Plan around pharmacy benefits policy making issues.

**Kim S.** What Factors Determine Doctors' Preferences for Original Drugs and Their Willingness to Prescribe Genetic Drugs in Korea? The 6TH World Congress On Health Economics held in Copenhagen, Denmark and Lund, Sweden July 7-11, 2007. Oral Presentation.


---

**Madeleine de Rosas-Valera, MD, MScI (Heidelberg)**

Dr. Madeleine de Rosas-Valera currently serves as Adviser to the Department of Health, Philippine Health Insurance Corporation and Private Hospital Association of the Philippines Inc. She is also teaches at the MBA Health Program of Ateneo Graduate School of Business. Dr. de Rosas-Valera was formerly the Undersecretary of Health in charge of the Cluster on Health Policy, Financing, Research, International Health and National Center for Pharmaceutical Management. She was also the Chairperson for the Formulary Executive Committee and Co-Chair for the DOH Research Hub. She was instrumental in the passing of the SIN Tax, Responsible Parenthood and Reproductive Health Law and chaired the drafting of their implementing rules and regulations. Her advocacy on the rational use of drugs and antibiotics led to the development of the Philippines National Plan to Combat Anti-Microbial Resistance. She was a Technical Officer for Patient Safety and Health Systems of WHO Western Pacific Region (2009-2012).

She is a senior health care service professional with more than two decades of professional expertise in health system and primary health care service delivery, financing and management in the public and private sectors. She has served in senior level positions with a national social health insurance organization, the Philippine Health Insurance Corporation (PHIC), responsible for Health Financing, Payment Mechanism, Contracting, Policy Development, Developing Standards of Accreditation, Developing the health care
benefits package covering TB and Maternity Care and Non-Communicable Diseases, and outpatient basic care package, drug and contraceptives devices reimbursement. Furthermore, the health sector considers Dr. de Rosas-Valera a champion of quality assurance, having been the leading figure in the implementation of PhilHealth’s mandate of quality assurance. Dr. de Rosas-Valera has been recognized for her leadership in advocating the importance of cost-benefit and cost-effectiveness analyses of drugs within the Philippine health care system. She has emphasized rational drug use in PhilHealth’s quality assurance program by supporting the Generics Act and adopting the 2005-2006 Philippine National Drug Formulary in PhilHealth’s benefit payment scheme. She has also promoted the use of evidence-based medicine and Health Technology Assessment in identifying drugs and procedures that can be included in the National Health Insurance Program (NHIP) benefit based on scientific evidence. She established and strengthened linkages with the different stakeholders of NHIP especially the academe whose expertise she recruited in doing health technology assessment for PhilHealth.

During her Fellowship, she developed and implemented a study of the economic burden of hospitalizations for hypertension for PhilHealth and of access to and use of antihypertensive medicines among PhilHealth members. The results of her research will inform PhilHealth as it decides how to implement outpatient medicines coverage for members with hypertension. She also studied the design of performance measures of medicines benefit policies and interacted with colleagues at Harvard Pilgrim Health Care and Neighborhood Health Plan around pharmacy benefits policy making issues.

Publications:


**Connie M. Trinacty, PhD**

Dr. Trinacty is assistant science director at the Kaiser Permanente Center for Health Research Hawaii (CHRH). Prior to joining CHRH, she was an assistant professor in population medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, an NIH trainee and a scholar in health disparities. She earned her doctorate in health policy from Harvard University, and her master’s degree in health policy and management from the Harvard School of Public Health.

During her Fellowship, Dr. Connie Trinacty was a candidate in the PhD Program in Health Policy at Harvard University. Her Fellowship research focused on issues of quality of care and self-management practices among chronically ill populations. During the first year of her Fellowship, her research focused on the impact of a quality improvement change to a diabetes health care delivery system and its impact on race-related barriers to effective care. During her second year, her research evaluated racial differences in adherence to long-term diabetes self-management practices, specifically medication use and glucose self-monitoring.
Publications:


Kara Zivin, PhD 2004-2006

Dr. Zivin is an Associate Professor, Department of Psychiatry, University of Michigan Medical School. Dr. Zivin’s research applies quantitative methods to mental health services and policy with a focus on predictors and consequences of depression in older adults and among Veterans. Her research examines cost-effectiveness of depression care, mortality risks among depressed patients, employment support needs among those with mood disorders, genetic and psychosocial contributors to late-life depression, and the impact of short and long term antidepressant use and adherence on depression, health, and cost outcomes.

Dr. Zivin was the recipient of a National Institute of Mental Health (NIMH) training grant and of an individual National Research Service pre-doctoral Fellowship through NIMH.
She earned her doctorate in health policy from the Harvard University Graduate School of Arts and Sciences.

Her Fellowship research focused on mental health care, in particular on the effects of a policy to improve adherence to antidepressant medications among members of Harvard Pilgrim Health Care.

**Publications:**


**Bambauer KZ, Locke SE, Aupont O, Mullan MG, McLaughlin TJ.** Using the Hospital Anxiety and Depression Scale to screen for depression in cardiac patients. *General Hospital Psychiatry.* 2005;27(4):275-84.


**Bambauer KZ, Prigerson HG.** The Stigma Receptivity Scale (SRS) and its association with mental health service use among bereaved older adults. *Journal of Nervous and Mental Disease.* 2006;194(2):139-41.

Rachel A. Elliott, Bpharm, MRPharmS, PhD

Dr. Elliott trained as an industrial pharmacist, was one of the first critical care specialist pharmacists in the UK, and gained a Department of Health funded PhD in health economics with Prof Martin Buxton (Health Economics Research Group, Brunel University). She has been in her current position since May 2007. Prior to this she was based at the School of Pharmacy, University of Manchester (1996 to 2007). Her Fellowship research, supported by the Commonwealth Fund Harkness Fellowship in Health Care Policy, addressed the economic impact of policies to improve adherence to medicine, as well as the barriers to taking medicines among the elderly with multiple illnesses.

Publications:


Niteesh K. Choudhry, MD, PhD

Dr. Choudhry is an internist and health services researcher whose work focuses on the development and evaluation of novel strategies to improve health care quality and reduce spending. He is Professor Medicine at Harvard Medical School, the founding Executive Director of the Center for Healthcare Delivery Sciences and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women's Hospital, where he is also a practicing hospitalist.

Dr. Choudhry received his clinical training in Ontario, and a graduate of the Harvard University PhD Program in Health Policy. His Fellowship research, supported by the Frank Knox Scholarship and a Canadian Institutes of Health Research Fellowship, addressed the impact of personal clinical experience on physician prescribing behavior.

Publications:


**Julie M. Donohue, PhD**

Dr. Donohue is Associate Professor and Vice Chair for Research in the Department of Health Policy and Management, in the Graduate School of Public Health. She is the Director of the Medicaid Research Collaborative and the Co-Director of the Center for Pharmaceutical Policy and Prescribing (CP3). She holds secondary appointments in the Clinical and Translational Science Institute and is a faculty affiliate in the Health Policy Institute and in the Center for Bioethics and Health Law.

Donohue earned a PhD in health policy from Harvard University and completed a post-doctoral fellowship in pharmaceutical policy research at Harvard Medical School. Her Fellowship research focused on the effects of pharmaceutical promotion to consumers and physicians.

**Publications:**


**Sylvia Park, MPH, PhD**

Dr. Park is a pharmacist and health policy researcher. During her first Fellowship year, she examined the impact of a policy in Korea to prohibit physicians from dispensing drugs on appropriate and inappropriate prescribing of antibiotic medications. During her second year, she studied the impact of the introduction of atypical antipsychotic agents on prescribing, compliance, and the incidence of side effects among patients with schizophrenia in the UK.
She is currently a senior research fellow at Korea Institute for Health and Social Affairs. Her research interests include pharmaceutical policy, physician prescribing behaviors and pharmaceutical industry.

**Publications:**


**Elizabeth E. Roughead, BPharm, GDip Health Prom, MAppSc, PhD**

Professor Roughead's research interests include public policy on medicines, rational drug use, adverse events and pharmacoepidemiology. Her Fellowship research, supported by the Commonwealth Fund Harkness Fellowship in Health Care Policy, focused on the variability in cyclooxygenase II inhibitor prescribing in state Medicaid programs, in relationship to Medicaid prescribing restrictions. She also developed a model to integrate drug utilization, safety, and expenditure evaluation and pharmaceutical policy making for the U.S. Centers for Medicare and Medicaid Services. Following her Fellowship, she returned to the School of Pharmacy and Biomedical Sciences at the University of South Australia. She is Director of the Quality Use of Medicines and Pharmacy Research Centre, a future fellow of the Australian Research Council, Principal Investigator of the Centre of Research Excellence in Post marketing surveillance of Medicines and Medical Devices, and Executive Director of the Veterans’ Medicines Advice and Therapeutics Education Services (MATES) project. She continues to serve as a member of the Australian Government advisory committee on drug utilization.

**Publications:**


**Siritree Suttajit, PhD**

Dr. Suttajit is a faculty member in the Pharmaceutical Care Department, Faculty of Pharmacy, Chiangmai University

23.
She was a Ph.D. candidate at Chulalongkorn University and a Fulbright Visiting Scholar during her Fellowship year. Her research focused on the factors that influence inappropriate use of medicines in treating adult respiratory infections in a slum community in Bangkok.

**Publications:**


Panos Kanavos, MSc, PhD

Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health. Panos is Visiting Professor at the University of Basel, Switzerland and also has a Visiting appointment with the London School of Hygiene and Tropical Medicine (LSHTM). He has previously been a Commonwealth Foundation Harkness Fellow in Health Care Policy in the Department of Population Medicine (formerly the Department of Ambulatory Care and Prevention), Harvard Medical School. Previous visiting appointments have included the University of Lausanne and the University of Delaware. He is an Economist by training, currently coordinates the Programme in International Health Policy at LSE and teaches Health Economics, Pharmaceutical Economics and Policy, Health Care Financing, and Health Systems Performance Measurement.

Panos' research interests include comparative health policy and healthcare reform, pharmaceutical economics and policy from a developed and developing country perspective, quality and access in healthcare, and socio-economic determinants of health.

**Publications:**


Sallie-Anne Pearson, BSc (Hons) PhD

Professor Sallie Pearson heads the Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Australia. She is also the Scientific Director the NHMRC Centre of Research Excellence in Medicines and Ageing and holds an Honorary Professorial Appointment at the Menzies Centre for Health Policy, University of Sydney. In 2015, Sallie was recognised for her research leadership in the post-market surveillance of cancer medicines with the NSW Premier’s Award for the Outstanding Cancer Research Fellow. Sallie consults regularly government organisations on matters pertaining to pharmacoepidemiology and health data linkage including her role as a research advisor to NPS MedicineWise and consultant to the Australia’s Therapeutic
Goods Administration. She is also actively engaged in a range committees and advisory groups including: Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee, Commonwealth Department of Human Services Research Advisory Committee; and NSW Population and Health Service Research Ethics Committee.

Sallie’s fellowship research focused on discriminatory effects, by race, of a state triplicate prescription program on benzodiazepine use. She also conducted a systematic review of interventions to improve medication use in health maintenance organizations.

Publications:


Jeanne Madden, PhD 2002-2003

Dr. Madden is Associate Professor in the Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Bouvé College of Health Sciences, at Northeastern University. She received a bachelor’s degree in History from Brown University, a master’s degree from the Harvard School of Public Health, and her doctorate from the Harvard University PhD program in Health Policy.

Dr. Madden’s research primarily concerns access to health care, the burden of costs on patients, and the consequences of health system changes. She has directed several federally-funded studies examining the impact of changes in pharmacy benefits on access to treatments for chronic illness. Dr. Madden is leading a qualitative study to gather perspectives of individuals with bipolar disorder navigating different insurance benefits, and leads stakeholder engagement activities for the PCORI-sponsored parent grant evaluating the impact of high-deductible insurance plans on adolescents and adults with bipolar disorder. In her recent research as part of the Mental Health Research Network, she has led inquiries into the completeness of information in medical record data and the use of psychotropics among children with autism spectrum disorders. She is co-investigator on a study of the impact of FDA warnings about antidepressants and suicidality among youth.

Past studies have examined medication underuse and uncontrolled asthma in a commercially-insured population, access to and affordability of medicines in low- and middle-income countries, and maternal and infant outcomes following changes in hospitalization policies at childbirth. Dr. Madden has particular expertise in large datasets, measurement development and validation, and evaluation methods. She holds a secondary faculty appointment at her prior institution, the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute.
She holds a master's degree in International Health Policy and Economics from the Harvard School of Public Health and a doctoral degree from the Harvard University PhD program in Health Policy.

**Publications:**


**Anita K. Wagner, PharmD, MPH, DrPH**

Dr. Anita Wagner is Associate Professor in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute in Boston, MA, USA.

For the past two decades, Dr. Wagner has contributed to or led applied research and capacity strengthening collaborations to improve—from a health systems perspective—medicines availability, access, affordability, and use, in the United States and in low and middle-income countries (LMIC). More recently, her work includes a focus on health system questions around highly priced, novel therapies.

She founded and directs the global Medicines and Insurance Coverage (MedIC) Initiative, which aims to support LMIC system leaders and operational staff in the design, implementation, evaluation, and routine monitoring of evidence-informed medicines policies and programs. Under the MedIC Initiative, collaborators have begun to establish a portfolio of research on pharmaceutical policies and programs in countries working toward universal health coverage (UHC).

Dr. Wagner co-directs the Harvard Medical School Fellowship in Pharmaceutical Policy Research and directs global MedIC Courses on Medicines in Health Systems. More than 200 professionals from governments, academia, and other organizations in more than 20 countries have participated in the courses. In 2016, the team launched the first online Course on Medicines in Health Systems Working Toward Universal Health Coverage on the World Bank Open Learning Campus.
Dr. Wagner also serves as a pharmacoepidemiologist on the FDA’s Sentinel Initiative, a national system that tracks the safety of pharmaceuticals in the United States.

Dr. Wagner received her Master of Public Health degree in international health and Doctor of Public Health degree in epidemiology from the Harvard School of Public Health. She holds a doctorate in clinical pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences and a German master-equivalent degree in pharmacy.

Her Fellowship research focused on the effects of regulating psychoactive drugs in Medicaid.

Publications:


**Alyce S. Adams, PhD**

Dr. Adams is a Research Scientist III, Division of Research (DOR) and Associate Director, Health Care Delivery and Policy, Kaiser Permanente Northern California studying healthcare disparities among insured populations. Her recent publications include longitudinal studies of the impact of state Medicaid programs to reduce medication costs on medication use and outcomes among adults with disabilities and racial and ethnic disparities in diabetes self-management and outcomes in a managed care setting. Her current research focuses on understanding and reducing disparities in pain assessment, management and impact.

Prior to joining DOR, Dr. Adams was on faculty at Harvard Medical School, Boston, MA. She has served on scientific review committees for the National Institutes of Health and has received mentoring awards from Harvard Medical School and the Agency for Healthcare Research and Quality. She received her PhD in Health Policy at Harvard University and her postdoctoral training at the Department of Population Medicine.
(formerly the Department of Ambulatory Care and Prevention) at Harvard Medical School and Harvard Pilgrim Health Care Institute, and continues to advise students, post doctoral fellows and clinical residents.

**Publications:**


